CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 114 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 3.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $16,000 | -33.3% | 1,666 | -35.5% | 0.00% | 0.0% |
| Q4 2019 | $24,000 | +14.3% | 2,584 | -26.2% | 0.00% | 0.0% |
| Q3 2019 | $21,000 | +110.0% | 3,500 | +335.3% | 0.00% | – |
| Q2 2019 | $10,000 | -9.1% | 804 | +13.1% | 0.00% | -100.0% |
| Q3 2018 | $11,000 | -62.1% | 711 | -58.0% | 0.00% | -50.0% |
| Q2 2018 | $29,000 | +190.0% | 1,694 | +142.0% | 0.00% | +100.0% |
| Q3 2017 | $10,000 | -41.2% | 700 | -30.0% | 0.00% | -50.0% |
| Q1 2017 | $17,000 | -76.7% | 1,000 | -85.9% | 0.00% | -77.8% |
| Q4 2016 | $73,000 | +128.1% | 7,100 | +121.9% | 0.01% | +200.0% |
| Q3 2016 | $32,000 | +14.3% | 3,200 | +28.0% | 0.00% | -25.0% |
| Q2 2016 | $28,000 | +27.3% | 2,500 | +56.2% | 0.00% | +33.3% |
| Q1 2016 | $22,000 | -60.0% | 1,600 | -44.8% | 0.00% | -66.7% |
| Q4 2015 | $55,000 | +189.5% | 2,900 | +107.1% | 0.01% | +200.0% |
| Q4 2014 | $19,000 | -51.3% | 1,400 | -54.8% | 0.00% | -40.0% |
| Q3 2014 | $39,000 | – | 3,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
| Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
| Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
| EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
| BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
| EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
| RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
| Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
| AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
| INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |